Evidence map›Paper›PMID 38059635›Full record

Trial reportAntimicrobial agents and chemotherapy2024

A phase I, randomized, double-blind, placebo-controlled, ascending single- and multiple-dose study of the pharmacokinetics, safety, and tolerability of oral ceftibuten in healthy adult subjects.

María Patricia Hernández-Mitre, Steven C Wallis, Elizabeth E Morgan, Michael N Dudley, Jeffery S Loutit, David C Griffith, Jason A Roberts

Abstract readRandomized Controlled TrialClinical Trial, Phase I
In one paragraph

Trial report in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

María Patricia Hernández-MitreUQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland , Brisbane, Queensland, Australia.ORCID 0000-0003-3565-0292
Steven C WallisUQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland , Brisbane, Queensland, Australia.
Elizabeth E MorganQpex Biopharma, Inc. , San Diego, California, USA.
Michael N DudleyQpex Biopharma, Inc. , San Diego, California, USA.
Jeffery S LoutitQpex Biopharma, Inc. , San Diego, California, USA.
David C GriffithQpex Biopharma, Inc. , San Diego, California, USA.ORCID 0000-0002-2922-3852
Jason A RobertsUQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland , Brisbane, Queensland, Australia.ORCID 0000-0001-6218-435X

Funding

DHAC | National Health and Medical Research Council (NHMRC) APP2007007DHAC | National Health and Medical Research Council (NHMRC) APP2009736HHS | Biomedical Advanced Research and Development Authority (BARDA) HHSO100201600026C
6 · The paper itself

Abstract

This was a phase I, randomized, double-blind, placebo-controlled, ascending single- and multiple-dose study of oral ceftibuten to describe the pharmacokinetics (PK) of

Indexed as

CeftibutenAdministration, OralAdultArea Under CurveDose-Response Relationship, DrugDouble-Blind MethodHealthy VolunteersHumansCeftibutenceftibutenpharmacokineticsphase Isafetytolerability

Identifiers

PMID38059635
PMCPMC10777847

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.